Physician profile

Bruce Garretson

Retina Specialist · Royal Oak, MI

NPI 1659308617

$4,140.09

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,512.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alimera Sciences, INC. $3,273.10 2019-2024 Iluvien, Yutiq
Regeneron Healthcare Solutions, INC. $231.63 2019-2023 Eylea, Eylea Hd
Abbvie INC. $163.68 2022-2024
Genentech USA, INC. $124.90 2022-2024 Vabysmo, Susvimo
Novartis Pharmaceuticals Corporation $121.97 2019-2020
Allergan, INC. $112.49 2021
Genentech, INC. $58.71 2019
Eyepoint US, INC. $53.61 2019-2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bruce Garretson

$4,140.09

in general payments reported 2019-2025

Years
2019-2024
Top company
Alimera Sciences, INC.

https://glasscript.com/doctor/74222/bruce-garretson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.